FDMT vs HD: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

HD is the larger of the two ($349.58B market cap): the incumbent the market prices for continued execution (21.97x forward earnings, beta 0.95). FDMT is the smaller challenger ($687.24M), priced similarly on forward earnings (-3.04x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.

FDMT vs HD: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricFDMTHDWhat it tells you
Market cap$687.24M$349.58BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E-3.0421.97Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Beta2.910.95Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range55% of range61% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book1.6821.04How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Before you buy: how FDMT and HD affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. FDMT and HD share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined FDMT and HD exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does 4D Molecular Therapeutics (FDMT) do?

4D Molecular Therapeutics, Inc. (Nasdaq: FDMT, and known as 4DMT) is an Emeryville, California biotech founded in 2013 that engineers adeno-associated virus (AAV) vectors through a directed-evolution platform the company calls Therapeutic Vector Evolution. Its lead candidate, 4D-150, pairs the proprietary R100 vector with a transgene encoding aflibercept plus an RNA interference approach against VEGF-C, delivered by a single in-office intravitreal injection. The goal is to replace repeated monthly or bimonthly anti-VEGF eye injections with one durable treatment. Two Phase 3 wet AMD trials are fully enrolled: 4FRONT-1 randomized 523 patients with topline data guided to Q2 2027, and 4FRONT-2 finished enrollment in June 2026 with more than 500 patients and topline guided to H2 2027. On September 28, 2026 the company enrolled the first patients in 4SIGHT, a 514-patient Phase 3 in diabetic macular edema comparing 4D-150 with aflibercept 2 mg every eight weeks, with a primary endpoint of non-inferior visual acuity at week 52. Behind the retina franchise sit 4D-175 for geographic atrophy, 4D-710 for cystic fibrosis lung disease, and 4D-725 for alpha-1-antitrypsin deficiency, all of which the company says it is advancing mainly through outside funding rather than its own balance sheet.

Full FDMT guide

What does The Home Depot (HD) do?

The Home Depot, Inc. is the world's largest home improvement retailer, operating approximately 2,300 stores across the United States, Canada, and other locations in North America. The company sells building materials, home improvement products, lawn and garden supplies, and provides installation and tool-rental services to two main customer groups: do-it-yourself homeowners (DIY) and professional contractors (Pros). Revenue is generated almost entirely through retail store sales and, increasingly, through digital channels (online sales reached 15.9% of total revenue in fiscal 2025) and through its specialty trade distribution arm, SRS Distribution, which serves Pros directly with roofing, landscaping, pool supplies, and now drywall and steel framing products following the September 2025 acquisition of GMS Inc. The company earns a gross margin of roughly 33% and an operating margin in the low-to-mid teens, with strong free cash flow that funds a steadily growing dividend (156 consecutive quarterly payments as of early 2026) and periodic share repurchases.

Full HD guide

FDMT vs HD: how do they differ?

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

  • FDMT drivers: Two fully enrolled Phase 3 wet AMD trials; Durability data that defines the commercial pitch.
  • HD drivers: Pro contractor ecosystem buildout; Pent-up housing demand and a potential mortgage rate cycle turn.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Everything concentrates in one molecule and two wet AMD readouts, so a miss or an ambiguous result in 4FRONT-1 or 4FRONT-2 would remove most of the reason to own the shares, and the new DME trial adds cost on the same molecule rather than diversification away from it. For HD, the most direct risk is a prolonged freeze in the US housing market: low inventory, elevated mortgage rates, and high home prices have kept transaction volumes near multi-decade lows, directly suppressing demand for the large remodeling projects that drive Home Depot's highest-ticket sales.

FDMT or HD: which should you pick?

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick FDMT if you believe its drivers more; HD if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the FDMT and HD guides.

FDMT vs HD: the full fundamentals

FDMT. Conventional multiples do not apply, because the revenue line is a licensing payment rather than a business. Stripping out the roughly $431 million of cash reported at June 30 and adding back $20 million of drawn Hercules debt leaves an enterprise value near $280 million on the common-share count at the October 16 price, so the market is assigning a few hundred million dollars to a Phase 3 asset in two multi-billion-dollar indications plus four earlier programs. Book value is the only anchor with real content here, at roughly $408 million of stockholders' equity at mid-year against an accumulated deficit of about $858 million. The shares traded between roughly $6.96 and $16.93 over the trailing year, and the average of 11 analyst targets is about $28.

HD. Home Depot grew total revenue 3.2% in fiscal 2025, mostly from the SRS and GMS acquisitions rather than organic comparable-store performance, which was essentially flat at +0.3%, and the fiscal second quarter of 2026 lifted revenue about 5.7% with EPS ahead of consensus. After a roughly 10% decline in 2026, the stock trades near 22x trailing and 19.5x forward earnings, below the ~23x it carried in mid-2026 but still above the peer group, and the dividend yield has risen to about 3%. Analysts expect fiscal 2026 EPS of about $15.02 and fiscal 2027 EPS near $15.99, so the multiple still assumes a housing recovery eventually shows up; the November 17 report is the next read.

Headline figures (approximate, October 2026): FDMT shows revenue (ttm) ~$92M, of which ~$85M was a one-time Otsuka upfront, product revenue $0, no approved products since inception, net loss (ttm / q2 2026) ~$179M / ~$72.9M, eps (q2 2026 vs estimate) ~$(1.04) vs ~$(1.02); HD shows revenue (ttm) ~$169.2 billion (fiscal 2025: ~$164.7 billion), q2 fy2026 revenue (ended aug 2, 2026) ~$47.9 billion, up ~5.7% year over year, q2 fy2026 eps vs estimate $4.92 vs $4.73, net earnings (ttm) ~$14.2 billion (~8.4% net margin).

The bottom line: FDMT vs HD

FDMT and HD are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined FDMT and HD exposure against your real portfolio. It is not an investment adviser.

Wondering how FDMT or HD fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about 4D Molecular Therapeutics

Ask Walnut's AI anything about FDMT and see how it fits what you own.

FAQ

What is the difference between FDMT and HD?

+

4D Molecular Therapeutics, Inc. The Home Depot, Inc. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is FDMT or HD the better stock?

+

Neither is universally better. HD is the larger incumbent; FDMT is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, FDMT or HD?

+

On forward P/E (as of November 2026), FDMT trades at -3.04x and HD at 21.97x, so FDMT is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both FDMT and HD?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of FDMT vs HD?

+

FDMT: Everything concentrates in one molecule and two wet AMD readouts, so a miss or an ambiguous result in 4FRONT-1 or 4FRONT-2 would remove most of the reason to own the shares, and the new DME trial adds cost on the same molecule rather than diversification away from it. Intravitreal AAV carries a specific safety history around intraocular inflammation and hypotony that has derailed competing programs, and long-term ocular safety in a several-hundred-patient Phase 3 population is a different test than an open-label Phase 2b. Cash burn ran near $70 million a quarter in the first half of 2026, and while the guided runway into the second half of 2028 covers the readouts, it does not cover a commercial launch, so further equity raises or partnerships are likely; a November 2025 offering and an active at-the-market program show how that has been funded before. Insiders sold shares worth about $0.8 million in September and $0.75 million in October 2026 per SEC filings. The competitive bar is also rising, since Roche's Vabysmo and Regeneron's higher-dose Eylea already stretch dosing intervals and aflibercept biosimilars are compressing the price of the incumbent standard; sector headlines move these stocks together, as when an EyePoint trial setback in August 2026 lifted FDMT and Kodiak and 4DMT updates in late September hit Ocular Therapeutix. Note the share count trap as well: roughly 55.2 million common shares were outstanding on August 10, 2026, alongside 16.9 million pre-funded warrants exercisable at $0.0001, so per-share and market-cap figures vary by source. On the positive side of the disclosure ledger, the Q2 2026 10-Q stated there were no material legal proceedings outstanding at June 30, 2026, and the company reported no going-concern qualification. HD: The most direct risk is a prolonged freeze in the US housing market: low inventory, elevated mortgage rates, and high home prices have kept transaction volumes near multi-decade lows, directly suppressing demand for the large remodeling projects that drive Home Depot's highest-ticket sales. Tariffs on imported goods (a significant portion of Home Depot's product mix is sourced internationally) could compress margins or require price increases that dampen consumer demand, even as management has worked to diversify its supply chain. The SRS and GMS acquisitions added substantial long-term debt to the balance sheet and pushed ROIC down to approximately 25.7% from 31.3%, and integration execution risk remains elevated while buybacks are paused. Total debt stood near $63 billion against about $2 billion of cash at the latest balance sheet. Finally, the stock trades at a trailing P/E of roughly 22x (about 19.5x forward), a premium to the broader retail industry, which leaves limited margin for error if earnings guidance is revised lower. The share price itself has already absorbed some of this: HD fell about 19% over the year to mid-October 2026 even as reported quarters beat estimates.

Related comparisons

Browse all stock comparisons.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell FDMT or HD; figures are approximate and dated (as of November 2026). Verify current data before investing.